AIRLINK 200.02 Increased By ▲ 6.46 (3.34%)
BOP 10.23 Increased By ▲ 0.28 (2.81%)
CNERGY 7.83 Decreased By ▼ -0.10 (-1.26%)
FCCL 40.00 Decreased By ▼ -0.65 (-1.6%)
FFL 16.80 Decreased By ▼ -0.06 (-0.36%)
FLYNG 26.50 Decreased By ▼ -1.25 (-4.5%)
HUBC 132.79 Increased By ▲ 0.21 (0.16%)
HUMNL 13.99 Increased By ▲ 0.10 (0.72%)
KEL 4.67 Increased By ▲ 0.07 (1.52%)
KOSM 6.57 Decreased By ▼ -0.05 (-0.76%)
MLCF 46.66 Decreased By ▼ -0.94 (-1.97%)
OGDC 211.89 Decreased By ▼ -2.02 (-0.94%)
PACE 6.89 Decreased By ▼ -0.04 (-0.58%)
PAEL 41.34 Increased By ▲ 0.10 (0.24%)
PIAHCLA 17.02 Decreased By ▼ -0.13 (-0.76%)
PIBTL 8.13 Decreased By ▼ -0.28 (-3.33%)
POWER 9.37 Decreased By ▼ -0.27 (-2.8%)
PPL 181.45 Decreased By ▼ -0.90 (-0.49%)
PRL 41.60 Decreased By ▼ -0.36 (-0.86%)
PTC 24.69 Decreased By ▼ -0.21 (-0.84%)
SEARL 112.25 Increased By ▲ 5.41 (5.06%)
SILK 1.00 Increased By ▲ 0.01 (1.01%)
SSGC 44.00 Increased By ▲ 3.90 (9.73%)
SYM 19.18 Increased By ▲ 1.71 (9.79%)
TELE 8.91 Increased By ▲ 0.07 (0.79%)
TPLP 12.90 Increased By ▲ 0.15 (1.18%)
TRG 67.40 Increased By ▲ 0.45 (0.67%)
WAVESAPP 11.45 Increased By ▲ 0.12 (1.06%)
WTL 1.78 Decreased By ▼ -0.01 (-0.56%)
YOUW 4.00 Decreased By ▼ -0.07 (-1.72%)
BR100 12,170 Increased By 125.6 (1.04%)
BR30 36,589 Increased By 8.6 (0.02%)
KSE100 114,880 Increased By 842.7 (0.74%)
KSE30 36,125 Increased By 330.6 (0.92%)

There are over 600 local pharma manufacturing units in Pakistan and this alone is evidence enough for a healthy competition amongst the pharma industry. Rather than spending its resources on unrealistic price controls, the Drug Regulator Authority Pakistan (DRAP) needs to focus on the real issues like quality and the availability of life saving drugs and make the industry viable in the interest of the patients of Pakistan.
"Lack of critical and life-saving medicines is an eventuality in a price-controlled environment and a nightmare for poor patients in absence of fallback options for the government which has declined to follow its own pricing policy devised more than a year ago, claimed pharmacy industry sources. "Price controls are never a long-term or a favourable solution for both the government and patients. Market forces determining prices of products are the best way forward for the Pakistan pharmacy industry," they said.
"The pharmaceutical industry has been demanding free pricing set by competitive forces or referencing to other countries with similar socio-economic indicators, such as the South Asian Association for Regional Cooperation, as more transparent method of fixing prices of registered medicines. Let's look at the ground realities. Price control impacts businesses, economy and the patients in multiple ways. It reduces the incentives for manufacturers to continue production of medicines as all other resources and materials used to manufacture keep on increasing."
The sources further said, "Once a company realises that the medicine in question is no longer viable, it may cut back resources for production resulting in less volume. This may be a first step to a complete shutdown of manufacturing. Although, there may be other players in the market, they will not take up manufacturing of a product that is not feasible financially.
"If the government puts the issues of the shortages of lifesaving medicines on priority, they must introduce incentives for the manufacturers to ensure or operate a manufacturing unit themselves meeting the demands of the local market. The government may also opt to import the medicines but this may be an expensive proposition as medicines are cheaper in Pakistan than majority of the countries where they are produced.
"Medicine prices are amongst the cheapest in Pakistan - 10 tablets of paracetamol cost less than Rs 10. In fact, most of the commonly used tablets and syrups have a price threshold of less than 2 or 3 rupees per dose. Ensuring quality to avert any untoward incident should be the utmost priority for the government. Quality lapse happens when we excessively control the prices and due to the unviability for quality manufacturers to produce drugs, less known and substandard alternatives flood the market.

Copyright Business Recorder, 2016

Comments

Comments are closed.